

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of: SCHWARTZ, et al

Serial No.: 09/622,199

Filed: August 14, 2000

For: NON-IMIDAZOLE ALKYLAMINES AS
HISTAMINE H₃ - RECEPTOR LIGANDS AND
THEIR THERAPEUTIC APPLICATIONS

Examiner

Art Unit

Docket No. P06853US00/LRP

#3
LB
8/15/01

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231
S I R :

This IDS is submitted herewith pursuant to 37 CFR. §1.97-1.98 and includes the following:

- ☒ A listing of the references on PTO-1449.
- ☒ A copy of references which have come to applicant's attention.
- ☒ A copy of a corresponding foreign Search Report explaining the relevance of those references.
- ☐ A separate explanation of relevance.

Please note the following particulars concerning the filing of this IDS:

- ☒ This IDS is filed **within three months** of the filing date of a national application other than a CPA, or within three months of the date of entry into the national stage as set forth in 37 CFR. §1.491 in an international application, before the mailing date of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination, whichever event occurs last.

☐ This IDS is filed **after a first action**, but before a final action, allowance, or any other action which closes prosecution, **and**:

☐ is accompanied by a check in the amount of \$180.00 required by 37 CFR. §1.17(p).

or

☐ I hereby state that each item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

☐ I hereby state that no item of information in this IDS herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR. §1.56(c) more than 3 months prior to the filing of this IDS.

☐ An appropriate statement is attached.

..... This IDS is filed **after a final action or allowance**, but on/before payment of the issue fee, **and**:
..... is accompanied by a check in the amount of \$180.00 required by 37 CFR. §1.17(p).

and

..... I hereby state that each item of information contained in this IDS was cited in a
..... communication from a foreign patent office in a counterpart foreign application not more
..... than three months prior to the filing of this IDS.

..... I hereby state that no item of information in this IDS herewith was cited in a
..... communication from a foreign patent office in a counterpart foreign application, or, to my
..... knowledge after making reasonable inquiry, was known to any individual designated in 37
..... CFR. §1.56(c) more than 3 months prior to the filing of this IDS.


..... An appropriate statement is attached.

..... This IDS is being filed pursuant to 37 CFR. §1.97(i), **for placement in the file.**

X If no check is enclosed and a fee is due in connection with this communication or if the check
..... enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due
..... with this communication to Deposit Account No. 12-0555. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: May 31, 2001


By: Linda R. Poteate

Registration No.: 36255

LARSON & TAYLOR, PLC • 1199 North Fairfax St. • Suite 900 • Alexandria, VA 22314

Substitute for Form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**Sheet 1 of 2

Application No.: 09/622,199

Filing Date: August 14, 2000

First Named Inventor: SCHWARTZ

Group Art Unit:

Examiner Name:

Attorney Docket No.: P06853US00/LRP

U.S. PATENT DOCUMENTS

<i>Initial</i>	<i>Document No.</i>	<i>Name</i>	<i>Date</i>	<i>Relevance</i>
DM	3,947,434	Spencer et al.	03/30/1976	
	4,751,302	Ibuki et al.	06/14/1988	
	3,312,696	Turbanti	04/04/1967	
DM	2,870,151	Wright et al.	01/20/1959	

FOREIGN PATENT DOCUMENTS

<i>Initial</i>	<i>Office</i>	<i>Number</i>	<i>Name</i>	<i>Date</i>	<i>Relevance</i>	<i>Trans</i>
	GB	1 512 880	Mitsubishi Chem Ind	06/01/1978		
	DE	1 269 134	Veb Deutsches Hydrierwerk Rodleben	12/18/1962		
	GB	924,961	The Wellcome Foundation Limited	05/01/1963		
	DE	26 24 261	Bottu FA	12/16/1976		
	DE	965 813	Abbott Laboratories	06/19/1957		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

<i>Initial</i>	<i>Name (in CAPS), Title of Article/Item, Date, Page(s), Volume-Issue No., etc.</i>	<i>Trans</i>
	LITTMANN E.R. and MARVEL C.S.: "Cyclic Quaternary Ammonium Salts from Halogenated Aliphatic Tertiary Amines"; J. Amer. Chem. Soc., vol. 52, 1930, pages 287-294, XP002084866 * page 289 - page 290 *	
	KIKUMOTO R., ET AL.: "Synthesis and Antidepressant Activity of Substituted (gamma-Aminoalkoxy) benzene Derivatives"; J. Med. Chem., vol. 24, no. 2, 1981, pages 145-148, XP000565653 * table 1 *	
	SHADBOLT R.S. ET AL.: "Some Aryloxyalkylamines, N-Arylethylenediamines and Related Compounds as Anorectic Agents"; J. Med. Chem., vol. 14, no. 9, 1971, pages 836-842, XP002084867 * table 1 *	

	WALSH D.A. ET AL.: "Synthesis and Antiallergy Activity of 4-(Diarylhydroxymethyl)-1-[3-(aryloxy)propyl]piperidines and Structurally Related Compounds"; J. Med. Chem., vol. 32, no. 1, 1989, pages 105-118, XP002084868 * tables I-III *	
	SOHDA T ET AL.: "Studies on Antidiabetic Agents. Synthesis of 5-4-(1-Methylcyclohexylmethoxy)-Benzyl)Thiazolidine-2,4-dione (Add-3878) and Its Derivatives"; Chemical and Pharmaceutical Bulletin, vol. 30, no. 10, 1982, pages 3580-3600, XP002046259 * table VIII *	
	CHABRIER P. ET AL.: "Nouveaux carbamates doués d'activité anesthésique locale"; Bull. Soc. Chim. Fr., 1955, pages 1353-1357, XP002084869 * table IV *	
	MARQUET J. ET AL.: "Topologically Controlled Coulombic Interactions, a New Tool in the Developing of Novel Reactivity. Photochemical and Electrochemical Cleavage of Phenyl Alkyl Ethers"; J. Org. Chem., vol. 60, no. 12, 1995, pages 3814-3825, XP002084870 * table 1 *	
	CASANOVAS A.-M. ET AL.: "Etude des relations structure-activité d'une série d'anesthésiques locaux"; Eur. J. Med. Chem.-Chim. Ther., vol. 17, no. 4, 1982, pages 333-337, XP002084871 * page 334 *	
	KIKUMOTO R ET AL.: "Syntheses and Platelet Aggregation Inhibitory and Antithrombotic Properties of 2-(Omega-Aminoalkoxy)Phenylethylbenzenes"; Journal of Medical Chemistry, vol. 33, no. 6, June 1990 (1990-06), pages 1818-1823, XP000673455 * tables I-III *	
	CHENEY L.C. ET AL.: "Alkylaminoalkyl Ethers of the Benzylphenols"; J. Amer. Chem. Soc., vol. 71, 1949, pages 60-64, XP002086293 * page 60; table I *	
	STARK H. ET AL.: "Developments of Histamine H3-receptor Antagonists"; Drugs of the Future, vol. 21, no. 5, 1996, pages 507-520, XP002084872 * page 507 *	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* Examiner: Initial if considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.